Combination therapy using Cel-CSO/Taxol NPs for reversing drug resistance in breast cancer through inhibiting PI3K/AKT/NF-κB/HIF-1α pathway.

The resistance of malignant tumors to multiple drugs is a significant obstacle in cancer treatment and prognosis. Accordingly, we synthesized a celastrol (Cel) prodrug (Cel-CSO) by conjugating chitosan oligosaccharides (CSO) to Cel for reversing Taxol resistance in chemotherapy, followed by self-assembly with Taxol into a novel nanoplatform of Cel-CSO/Taxol nanoparticles (termed NPs). NPs showed a suitable size (about 153 nm), excellent stability and prolonged release of Cel and Taxol in a manner that depended on both pH and time.

Non-Steady State NMR Effect and Application on Time-Varying Magnetic Field Measurement.

The measurement of a time-varying magnetic field is different from a constant magnetic field, due to its field intensity variation with time. Usually, the time-varying magnetic field measurement converts the solution of the magnetic induction intensity into the calculation of the induced electromotive force (EMF); then, the magnetic induction intensity is obtained by the time integration of the EMF, but the process is vulnerable to external interference. In this paper, a non-steady state nuclear magnetic resonance (NSS-NMR) scheme for the measurement of a time-varying magnetic field is proposed.

Blocking MG53 Phosphorylation Protects Diabetic Heart From Ischemic Injury.

Background: As an integral component of cell membrane repair machinery, MG53 (mitsugumin 53) is important for cardioprotection induced by ischemia preconditioning and postconditioning. However, it also impairs insulin signaling via its E3 ligase activity-mediated ubiquitination-dependent degradation of IR (insulin receptor) and IRS1 (insulin receptor substrate 1) and its myokine function-induced allosteric blockage of IR. Here, we sought to develop MG53 into a cardioprotection therapy by separating its detrimental metabolic effects from beneficial actions.

Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer.

Celastrol is a promising antitumor drug candidate, but the poor water solubility and cytotoxicity limit its clinical application. Herein, we synthesized a Celastrol (Cel)-chitosan oligosaccharide (CSO) conjugate (Cel-CSO) for drug delivery. Celastrol was conjugated to a CSO backbone via amide bond formation, which was verified by infrared spectrum (IR) analyses.